tm
Seeing Is Believing
tm
Seeing Is Believing
Currently, out of the existing stock ratings of Christopher Neyor - 9 which are a Hold (52.94%), 1 which are a Sell (5.88%), 7 which are a Buy (41.18%)
Analyst Christopher Neyor works at JPMORGAN and is covering the Healthcare sector with 26 price targets and ratings displayed on 2 stocks.
Christopher Neyor's average stock forecast success ratio is 41.67% with an average time for price targets to be met of 91.5 days.
Most recent stock forecast was given on KALA, Kala Pharmaceuticals at 30-Mar-2022.
Analyst best performing recommendations are on PCRX (PACIRA BIOSCIENCES).
The best stock recommendation documented was for PCRX (PACIRA BIOSCIENCES) at 11/2/2018. The price target of $50 was fulfilled within 3 days with a profit of $0.32 (0.64%) receiving and performance score of 2.12.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
52
$17.51 (50.77%)
60
1 months 18 days ago
9/17 (52.94%)
$16.87 (36.56%)
291
Buy
50
$15.51 (44.97%)
80
1 months 18 days ago
17/23 (73.91%)
$14.11 (30.71%)
490
Buy
63
$28.51 (82.66%)
68
1 months 18 days ago
8/18 (44.44%)
$19.4 (41.33%)
162
Hold
50
$15.51 (44.97%)
50
1 months 18 days ago
1/3 (33.33%)
$4.8 (12.67%)
26
Hold
52
$17.51 (50.77%)
60
8 months 15 days ago
25/28 (89.29%)
$1.94 (3.07%)
65
What Year was the first public recommendation made by Christopher Neyor?
